argenx appoints Karl Gubitz as Chief Financial Officer
argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced the appointment of Mr. Karl Gubitz as Chief Financial Officer. Mr. Gubitz brings to argenx nearly 20 years of global pharmaceutical leadership experience, specifically in financial planning and analysis, business partnerships and product commercialization. He will succeed Eric Castaldi, who will remain with the company through June 30, 2021.
“We are delighted to welcome Karl to our executive leadership team as he has an impressive track record of successfully establishing commercial organizations and providing strategic financial direction for global biopharmaceutical companies,” said Tim Van Hauwermeiren, CEO of argenx. “Karl’s insight and financial expertise will make him an indispensable member of the team as we advance our vision of developing an integrated, innovative, global immunology organization that aims to impact the lives of patients.”
“On behalf of the argenx management team and Board of Directors, we thank Eric for his significant contributions as we have grown from a private company to a near-commercial organization. It has been a pleasure working with him and we are grateful for the integral role he played in our growth and success over the last seven years. He will always be a part of the argenx family and we wish him well in all his future ventures,” added Mr. Van Hauwermeiren.
Mr. Gubitz has nearly 20 years of experience as a senior finance professional in the pharmaceutical industry at Pfizer, where he most recently served as Vice President of Finance within the Global Oncology business. At Pfizer, he successfully negotiated the commercialization model for tanezumab with Eli Lilly in all non-U.S. markets as well as the Myovant co-commercialization agreement for Orgovyx™. Within Pfizer, Mr. Gubitz has held country, regional, and global positions, and consistently delivered top-line growth. He has managed teams of over 250 colleagues in roles such as Vice President of Finance in the Global Internal Medicine business and Vice President of Finance, North America in the Global Innovative Products business. Prior to joining Pfizer in 2003, Mr. Gubitz held various management roles at PricewaterhouseCoopers. Mr. Gubitz holds a Master of Business Administration from Henley Management College in the United Kingdom, a Bachelor of Computing from the University of South Africa, and a Bachelor of Commerce from the University of Pretoria.
“This is a particularly exciting time to be joining argenx, as the Company nears the first potential commercial launch of its lead product, efgartigimod,” said Mr. Gubitz. “I look forward to working alongside this talented team as we transition to a commercial-stage company and grow argenx’s global immunology footprint to improve the lives of patients suffering from a variety of autoimmune diseases.”
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit www.argenx.com.